Charité is one of the largest university hospitals in Europe. All of our clinical care, research and teaching is delivered by physicians and researchers of the highest international standard. Charité proudly lays claim to more than half of all German Nobel Prize winners in Physiology or Medicine, including Emil von Behring, Robert Koch, and Paul Ehrlich. Charité is internationally renowned for its excellence in teaching and training. Charité – Universitätsmedizin Berlin represents a single medical faculty, which serves both Humboldt Universität zu Berlin and Freie Universität Berlin. Charité extends over four campuses, and has close to 100 different Departments and Institutes, which make up a total of 17 different CharitéCenters. Having marked its 300-year anniversary in 2010, Charité is now one of the largest employers in Berlin, employing 16,300 staff (or 19,400 if including its subsidiaries), and with a total annual turnover of €2.2 billion (including external funding and investment grants).
European Federation of National Associations of Orthopaedics and Traumatology (EFORT)
The European Federation of National Associations of Orthopaedics and Traumatology (EFORT) is the platform organisation linking Europe‘s national orthopaedic associations. Its aims reflect the will of all the participating associations to promote the exchange of scientific knowledge and experience in the field of prevention and both the conservative and surgical treatment of diseases and injuries concerning the musculoskeletal system. To this end, particular emphasis is placed on activities focusing on education and research.
Tissue Engineering and Regenerative Medicine International Society
The Tissue Engineering & Regenerative Medicine International Society - EU Chapter (TERMIS-EU) is dedicated to fostering a worldwide exchange of knowledge, all with the ultimate goal of enhancing patient outcomes on a global scale. It is committed to realizing its mission through several key pillars, including exemplary governance, knowledge dissemination, cross-disciplinary interaction, research advancement, empowering future leaders and policy advocacy.
The core values that underpin this endeavour are honesty, respect, scientific excellence, integrity, collaboration, social responsibility, diversity and transparency as the guiding principles for this international community as they work collectively to advance tissue engineering and regenerative medicine, ultimately contributing to improved patient outcomes worldwide.
BIH: Berlin Institute of Health
The mission of the BIH is medical translation: The BIH aims to translate findings from biomedical research into new approaches for personalised prediction, prevention and therapy and, conversely, to develop new research approaches from clinical observations.
The BIH is not a typical research institute. Its innovative approach is to utilize a novel concept of clinically-anchored cross-organ systems medicine in a comprehensive translational ecosystem to significantly increase the speed and effectiveness of medical translation. One of the main reasons for the success it enjoys in translational research is the clinical and scientific environment at the Charité and across Berlin, enabling a high degree of interaction due to the proximity of different partners. The MDC (Max Delbrück Center for Molecular Medicine) is central to the development of technologies and new mechanistic approaches.
Heraeus, the technology group headquartered in Hanau, Germany, is a leading international family-owned portfolio company. Your competitive advantage is our priority. In all our businesses our people combine material expertise with technological know-how. With this professional knowledge, we look into your processes, challenges and markets and develop high quality solutions that strengthen your competitiveness in the long term.
BONESUPPORT AB is a Scandinavian orthobiologics company that develops and markets CERAMENT®, an innovative range of radiopaque injectable osteoconductive and drug-eluting bioceramic products that have a proven ability to heal defects by remodelling to host bone in six to twelve months.
Their products have an indication for treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery.